Teva Migraine Drug Scores In Race With Alder, Lilly
Israeli drug giant Teva Pharmaceutical Industries (TEVA) reported successful midstage trial results for its novel migraine treatment and appointed a new head of business development Monday, sending its stock to a five-year high above 63. Teva reported results for a phase 2b study of TEV-48125, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody treating episodic migraines. The trial met its endpoint of a statistically significant